Anticipated Questions & Counterarguments

This is the most predictable response CASP can make, and it is worth addressing head-on: this statement is not about whether quality standards should exist. We explicitly support quality standards. The statement says so, at length, in multiple places.

The argument here is narrower and more specific: a trade association whose board members financially benefit from the standards it sets, which wholly owns the accreditation body whose standards it lobbies payers to require, has a structural conflict of interest that disqualifies it as a legitimate, independent standards body — regardless of whether those standards have merit on paper.

Dismissing this as competitive grievance doesn't address the conflict of interest. It evades it. If CASP's governance structure would be disqualifying at the Joint Commission, at ANSI, or at any other serious standards body in American healthcare — and it would be — then the question of whether the standards are good or bad is secondary to the question of whether the process for setting them is trustworthy.

We invite CASP to rebut the governance argument on its merits.

We agree. The statement explicitly acknowledges this: "CASP offers its members genuine resources. Its continuing education library, organizational guidelines, state advocacy infrastructure, and peer networking opportunities have real value."

But value to members does not confer authority over non-members. Member benefits do not neutralize structural conflicts of interest. An organization that provides useful resources to its dues-paying members is not, by that fact alone, entitled to set standards of care for an entire profession, seek regulatory recognition for its own subsidiary's accreditation body, and represent itself as the authoritative voice of a field it was never democratically authorized to speak for.

These are different claims. They require different accountability. CASP conflates them routinely.

CASP does describe ACQ as having independent committee structures. But structural independence is not achieved by forming independent committees within a wholly-owned subsidiary. The parent organization controls the subsidiary's existence, staffing, funding, and strategic direction. No committee's operational independence changes that fundamental relationship.

More directly: CASP's own CEO publicly stated in early 2026 that ACQ "in the initial years wouldn't have been able to make ends meet" without CASP's direct financial support. An organization that cannot pay its own bills without the trade association keeping it alive is not independent of that trade association — regardless of how its governance documents are written.

For comparison: The Joint Commission, which accredits hospitals and health systems in the United States, operates as a genuinely independent nonprofit with a board that includes consumer representatives, nursing professionals, physicians, and public members — specifically to prevent the type of industry capture that CASP's structure enables by design.

Open membership and meaningful representation are not the same thing. Small providers can pay CASP's dues. They cannot seat board members, shape governance decisions, or influence the standards being developed in their name. CASP's board is composed entirely of executives from its member organizations — overwhelmingly large, multi-state providers — with no independent seats, no clinician representation, no family representation, and no pathway for small-provider interests to influence governance outcomes.

An organization whose board is structurally dominated by the executives of large provider companies will predictably write standards that reflect the operational realities of large provider companies. That is not a cynical interpretation of CASP's behavior. It is the documented outcome of its governance structure.

The ABA market is highly fragmented — even the nine largest providers account for less than 30% of industry revenue. But small and independent providers, who represent the majority of the market by organization count, have no meaningful pathway to governance influence in the organization claiming to represent them.

There is a difference between consultation and governance. CASP may solicit input from various stakeholders — that is not the same as giving those stakeholders binding authority over the outcome. The question is not whether CASP asked anyone for feedback. The question is who made the final decisions, and whether those decision-makers had a personal financial stake in the outcome.

The answer to the second question is unambiguous: every member of CASP's board simultaneously leads a CASP member organization that directly benefits from the standards the board sets. That conflict of interest exists regardless of how many listening sessions preceded the final vote.

This claim deserves scrutiny on its own terms before it is accepted as a rebuttal. What independent evidence exists that ACQ-accredited organizations deliver measurably better clinical outcomes than non-accredited organizations? Where is the peer-reviewed research? Where is the independent evaluation conducted by a body with no financial interest in the answer?

Accreditation standards can improve quality. They can also serve as barriers to market entry that disadvantage smaller competitors — particularly when the accreditation body is wholly owned by a trade association whose largest members helped write the standards and already have the compliance infrastructure to meet them.

The claim that accreditation improves quality is a hypothesis. In the absence of independent evidence, accepting it as a settled fact — particularly from the organization selling the accreditation — is not scientifically or regulatorily appropriate.

The conflict extends to how CASP produces the clinical evidence it presents to payers and federal agencies. Its white paper Evidence About ABA Treatment for Young Children with Autism: The Impact of Treatment Intensity on Outcomes — cited in CASP's own March 2026 response to federal scrutiny following Wall Street Journal coverage — argues for high-intensity service delivery of 30 or more hours per week. The paper is presented as objective clinical guidance. It does not disclose that CASP's board is composed entirely of executives from large, clinic-based, high-volume provider organizations whose revenue scales directly with the treatment hours that payers authorize. An organization producing white papers advocating for high service volumes, governed by executives who profit from high service volumes, and presenting those papers to the agencies that set reimbursement policy — without disclosing that interest — is not engaged in disinterested science. Whether the underlying research has merit is a separate question from whether a financially interested party should be the one curating and lobbying on its basis.

CASP's tax status is technically disclosed in its IRS filings, which are publicly available as required by law. But there is a meaningful difference between legal disclosure and active transparency. When CASP lobbies payers, legislators, and federal agencies as "the voice of the autism provider community" — without prominently noting that it is a 501(c)(6) trade association whose legal obligation runs exclusively to its dues-paying members — policymakers and payers are being asked to make decisions without full information about the nature of the entity lobbying them.

The distinction between a 501(c)(6) and a 501(c)(3) is not a technicality. It is the difference between an organization legally required to serve the public interest and one legally permitted to serve its members' business interests as a primary purpose. That distinction is material to every policy decision CASP is asking regulators and payers to make.

They do — and that is precisely the problem. CASP holds a BACB-Authorized Continuing Education (ACE) provider designation and operates a library of over 70 courses worth more than 100 BACB CEUs, including training it has positioned as required to properly use the ABA Practice Guidelines it stewards. On its surface this looks like member value. Examined structurally, it is a toll booth.

BCBAs must earn continuing education credits to maintain their BACB credentials. CASP controls the guidelines that define clinical practice in the field. CASP then sells the training practitioners need to use those guidelines. The same organization that sets the standards, lobbies payers to require them, accredits compliance with them, and owns the data infrastructure used to evaluate network adequacy is also charging the practitioners those standards govern for the education required to implement them.

Providing CEU resources is not inherently problematic. Doing so as one interlocking layer of a commercial ecosystem in which the same trade association writes the rules, accredits compliance, owns the data, and sells the training — while claiming to represent the field's clinical interests — is a different matter entirely. The value of the product does not neutralize the conflict of the structure.

Section 501(c)(6) of the Internal Revenue Code designates business leagues and trade associations — entities whose primary purpose is to advance the commercial interests of their members. This is meaningfully different from a 501(c)(3) nonprofit, which requires an organization to serve a public charitable, scientific, or educational purpose and restricts financial self-dealing.

A 501(c)(6) organization's legal obligation runs to its dues-paying members. It is explicitly permitted to engage in lobbying as a primary activity, to advance members' business interests, and to generate revenue that benefits those members — none of which would be permissible as a primary purpose for a 501(c)(3).

This matters because CASP presents itself to payers, regulators, and federal agencies as if it were a neutral, public-interest clinical standards organization. Its legal structure tells a different story. When a 501(c)(6) trade association successfully lobbies payers to require accreditation from its own wholly-owned subsidiary, that is not a public health initiative. It is a commercial strategy operating under clinical cover.

Trade associations are indeed self-selected — that is their nature and their right. The problem is not that CASP is a trade association. The problem is that CASP is a trade association that has claimed the authority to speak for an entire professional field, set its clinical standards, accredit compliance with those standards, own the data infrastructure used to measure field performance, and lobby federal agencies to codify all of the above — without ever being authorized to do any of it by the field it claims to represent.

The National Restaurant Association represents restaurant owners. It does not claim to represent all Americans who eat food. The Chamber of Commerce represents businesses. It does not claim to represent all Americans who work. CASP's claim — that it represents "the autism provider community to the nation at large" — is categorically different from a trade association advocating for its members. It is a claim of field-wide representative authority that CASP was never granted.

Legitimate governance structures in analogous healthcare fields share common characteristics that CASP lacks:

• A board with balanced representation across stakeholder groups — not just the financial beneficiaries of the standards being set
• Meaningful inclusion of frontline clinicians, researchers, and — critically — consumers and families
• Accreditation bodies that are structurally independent of the trade associations whose members they accredit
• Transparent standards development processes with published rationales and comment periods
• No financial interest by the governing body in the outcome of its own standards decisions

The Joint Commission, ANSI, and NCQA all operate on versions of these principles. CASP operates on none of them. The field does not lack for governance models — it lacks the organizational will to apply them to the entity that has self-appointed as the field's standards authority.

The RBT credential is the BACB's answer to a basic question: who is qualified to sit with an autistic child and deliver behavior-analytic intervention? It establishes a minimum standard of training, competency verification, and ongoing supervision for the frontline practitioners who deliver the majority of direct ABA therapy hours to autistic individuals.

CASP's documented opposition to mandatory RBT enrollment in Medicaid programs — on its own public advocacy page — is opposition to the mechanism by which state programs verify that the people billing for services to autistic children actually hold that credential. Opposing enrollment requirements is not a neutral administrative position. It is opposition to accountability.

The reason this opposition exists is not clinical. It is financial: RBT certification requires training investment, examination fees, and ongoing supervision costs. Uncredentialed technicians are cheaper to hire and faster to onboard. Large provider organizations whose staffing models depend on high-volume hiring and rapid turnover have a direct financial interest in preserving maximum flexibility to staff direct service positions without credentialing requirements.

The ABA Practice Guidelines were originally published by the Behavior Analyst Certification Board and transferred to CASP in March 2020. The transfer itself is not the problem. The problem is what CASP has done since receiving them.

CASP now: (1) monetizes the guidelines by requiring insurance companies who use them for coverage decisions to pay for commercial access and complete CASP-sponsored training; (2) invokes the guidelines' authority in lobbying CMS, TRICARE, the Department of Labor, and the Department of Defense; and (3) simultaneously lobbies against mandatory enforcement of the BACB's own frontline credential — the RBT — in the very states where those guidelines are being used to justify coverage decisions.

The scientific and professional legitimacy those guidelines carry derives from the BACB's credentialing rigor and from decades of peer-reviewed behavioral research. When CASP lobbies payers to defer to "its" guidelines, it is trading on authority it did not generate — while actively undermining the credentialing framework that gives that authority its meaning.

This framing — that credentialing requirements are "bureaucratic burden" — is precisely the argument large provider organizations make when credentialing creates costs for their staffing models. It deserves examination.

RBT certification is not a complex or unreasonable requirement. It is a 40-hour training requirement, a competency assessment, and a background check, followed by a national examination. This is the baseline the BACB determined was necessary to safely deliver frontline ABA services to autistic children. Calling this a bureaucratic burden is a financial argument dressed as a clinical one.

For comparison: the state of Indiana — where CASP deployed lobbyists to defeat RBT enrollment requirements — was asking that the people billing Medicaid for services to autistic children hold the field's own frontline credential. That is not an unreasonable consumer protection requirement. It is the floor.

Dr. Jon Bailey, the BACB's founding director and one of the field's most prominent ethics authorities, has identified the shift from clinician-supervised to less-credentialed technician-delivered services as "an erosion of the foundation" of applied behavior analysis. CASP's advocacy posture actively protects that erosion at the policy level.

They can — if they can afford it. The issue is not technical eligibility. It is the compounding cost structure that accreditation imposes, and who bears that cost most heavily.

ACQ accreditation requires documentation systems, quality assurance processes, internal audit capacity, and ongoing administrative infrastructure. For a national multi-state provider with a compliance department, these requirements represent a marginal addition to existing overhead. For a BCBA running a community-based practice with a small clinical team, achieving and maintaining accreditation means either diverting clinical time to administrative compliance or hiring dedicated administrative staff whose salary the practice cannot absorb.

The requirement is identical on paper. The burden is not. And this is not a coincidence — it is the predictable outcome of standards written by executives of large organizations, for the operational realities of large organizations, with no independent voice from the small providers who will bear the compliance burden. Each new CASP product that becomes a de facto network requirement adds another layer of this compounding disadvantage.

Independent, community-based, and clinician-owned ABA practices are disproportionately likely to serve underserved communities, to maintain the kind of individualized, relationship-based clinical relationships that behavioral science supports, and to be operated by practitioners whose primary accountability is to their clients rather than to investor returns.

Research on the consequences of private equity's dominance in ABA specifically — and healthcare broadly — documents a consistent pattern: cost-cutting on clinical staffing, reduced supervision ratios, higher caseloads, and clinic closures when returns underperform. PE-backed ABA chains including the Center for Autism and Related Disorders, Invo Healthcare, 360 Behavioral Health, and Elemy have undergone bankruptcy, mass layoffs, and closure in recent years, leaving families without providers.

When the compliance infrastructure required to participate in payer networks is built for large corporate organizations, and when the organization building that infrastructure is governed by large corporate executives, the practical consequence is the progressive elimination of the providers least likely to put investor returns ahead of clinical outcomes. That has direct, documented consequences for the families who depend on them.

This statement was prepared by credentialed behavior analysts and independent ABA providers. The coordinating author is identified to signatories through the endorsement verification process. Initial anonymous presentation reflects a realistic assessment of professional retaliation dynamics in a field where a single trade association controls accreditation required for network participation.

We would note that the use of anonymous authorship in the initial publication of a professional critique is neither unusual nor ethically problematic — particularly when the substance of the critique is documented entirely in publicly available materials. Every claim in this statement can be verified by any reader directly from CASP's own website, CASP leadership's public statements, and peer-reviewed research. The identity of the author does not change the factual basis of a single argument.

As endorsements accumulate, the statement will increasingly speak in the names of the practitioners who sign it. We welcome CASP's response to the substance of the arguments, rather than to the question of who made them.

No. The statement is explicit on this point: "We are not arguing that CASP should not exist, that providers should not join it, or that its resources are without merit."

CASP is entitled to be a trade association that advocates for its members. It is entitled to offer continuing education, networking, and organizational resources. It is entitled to lobby for its members' interests. These are legitimate functions of a 501(c)(6) organization.

What CASP is not entitled to — absent independent governance, transparent standards development, and genuine multi-stakeholder representation — is the authority it has claimed: to set clinical standards for an entire profession, to accredit compliance with those standards through a wholly-owned subsidiary, to represent those standards as the field-wide consensus to payers and federal agencies, and to do all of this under the banner of clinical quality rather than commercial advocacy.

The decision to ground every claim in CASP's own public materials was deliberate, not limiting. It means that CASP cannot dispute the factual basis of any argument in this statement without contradicting its own published content. There is no interpretation required — the structural conflicts of interest, the timeline of acquisitions, the advocacy positions on RBT enrollment, the CEO's statements about ACQ's financial dependency: all of these come from CASP's own website, CASP's own advocacy page, or CASP leadership's own public statements.

We chose not to rely on secondary sources, third-party analyses, or insider accounts precisely so that the factual foundation of this statement would be unimpeachable. If CASP believes a factual claim in this statement is inaccurate, we invite them to identify it and provide documentation to the contrary. We will review and correct any genuine error.

What we will not accept is the characterization that documenting an organization's own disclosed conduct constitutes cherry-picking.

The statement identifies specific, concrete reforms. They are not radical. They are the governance standards that legitimate standards bodies in comparable healthcare fields are already expected to meet:

• Restructure CASP's board to include independent members who do not hold executive leadership roles at CASP member organizations — including clinician representatives, family representatives, and independent researchers
• Establish genuine structural independence for ACQ from CASP, including independent governance, funding, and staffing — not just independent committees within a wholly-owned subsidiary
• Develop clinical standards through transparent, multi-stakeholder processes with published rationales and public comment periods
• Disclose CASP's 501(c)(6) status prominently in all advocacy materials directed at payers, regulators, and federal agencies
• Cease lobbying against mandatory RBT credentialing requirements in Medicaid and other payer programs, consistent with the consumer protection purpose of the BACB guidelines CASP stewards

None of these requirements would prevent CASP from continuing to serve its members. They would, however, make CASP's claim to speak for the field and set its standards more than self-assertion.